PMH12 Risk of Relapse and Hospitalization in the 2-Year Open-Label Treatment of Outpatients with Schizophrenia Randomized to Olanzapine Long-Acting Injection or Oral Olanzapine
Nov 1, 2011, 00:00 AM
10.1016/j.jval.2011.08.314
https://www.valueinhealthjournal.com/article/S1098-3015(11)01876-6/fulltext
Section Title :
Mental Health
Section Order :
288
First Page :
A288
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)01876-6&doi=10.1016/j.jval.2011.08.314